Rate My Professor Eva Forssell-Aronsson

Eva Forssell-Aronsson is Professor of Medical Radiation Sciences, Head of the Department of Medical Radiation Sciences at the Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, and Principal Medical Physicist there. She has served as Senior Medical Physicist at Sahlgrenska University Hospital's Department of Medical Physics and Biomedical Engineering since January 1992 and as Full Professor at the Department of Radiation Physics since July 2000. Her research centers on systemic radionuclide therapy for cancer patients with metastatic disease, with a particular emphasis on neuroendocrine tumors. The Forssell-Aronsson Lab, part of the Sahlgrenska Translational Neuroendocrine Cancer Group and affiliated with the Sahlgrenska Center for Cancer Research, aims to develop, optimize, and apply new radiopharmaceuticals for therapy while enhancing understanding of ionizing radiation effects on tumor and normal tissues in vivo.

Specific efforts include optimizing treatments with radiolabeled somatostatin analogues like 177Lu-octreotate and norepinephrine analogues such as 131I-MIBG through strategies like priming schedules, receptor modulation, combination therapies with radiosensitizers, and kidney protection agents to boost anti-tumor effects and reduce toxicity. Translational studies span cell cultures, animal models, and patients, incorporating pharmacokinetic and dosimetric analyses, imaging techniques including multi-parametric MRI, histopathology, and molecular methods like PCR, sequencing, and epigenetics. She received the largest grant of SEK 13 million from the Lundberg Research Foundation in 2021. Her prolific publication record features highly cited works such as 'Optimization of cell viability assays to improve replicability and reproducibility of cancer drug sensitivity screens' (2020), 'Specific growth rate versus doubling time for quantitative characterization of tumor growth rate' (2007), 'Low-energy electron emitters for targeted radiotherapy of small tumours' (2001), and recent contributions like 'Local treatment of liver metastases by administration of 177Lu-octreotate via isolated hepatic perfusion' (2019) and 'rA1M is a potential kidney protector in 177Lu-octreotate treatment of neuroendocrine tumors' (2019), amassing over 5,800 citations.